Founded in 2014, Edinburgh Molecular Imaging (EM Imaging) is a clinical phase biotechnology company focused on enabling image guided therapy.
The company’s molecular imaging technology, based on Fluorescent Imaging, has the potential to detect disease in real-time during interventional procedures including surgery, providing more accurate treatment while sparing healthy tissue.
The focus of EM Imaging is the discovery and development of small molecules and peptides that, when conjugated with fluorescent dyes, target and specifically bind with cancerous cells and other diseased tissue. This illumination will provide the clinician with a clearer view of the extent of disease and thus a decision-making tool to benefit the patient. This technology is based on pioneering work undertaken at Edinburgh University.
The EM Imaging team has decades of documented success in imaging agent discovery and development with expertise spanning medicinal chemistry, biochemistry and cell biology, along with direct clinical expertise. The team also has significant expertise in the clinical development, approval and reimbursement of molecular imaging agents.
EM Imaging plans to become a leader in offering targeted fluorescent optical imaging agents as a cost effective and accessible imaging modality.